Literature DB >> 9894803

The age distribution of primary open angle glaucoma.

M W Tuck1, R P Crick.   

Abstract

Prevalence data for primary open angle glaucoma (POAG), taken from eight population surveys, was smoothed by curve-fitting to derive composite estimates with respect to quinqennial age groups from 40-44 to 85-89 years. These were applied to national population figures to provide a distribution of cases with respect to age. Estimated prevalence for age 40-89 years in mainly white Caucasian people was 1.2%, rising from 0.2% for those in their 40s to 4.3% for those in their 80s. Of the total cases, 7% were less than 55 years old, 44% were aged 55-74 years, and 49% were older. 'Implied incidence' was estimated from the prevalence results, being 0.11% per year in people aged 55 to 74 years. The analysis applied to relatively narrow definitions of POAG. If 'probable' cases and also 'ocular hypertensives requiring treatment' (of relevance for glaucoma screening) were included, the prevalence would be almost twice as high. Also, a larger proportion of potential cases for a screen would be less than 55 years old, partly because the average age of incident (i.e., newly developed) cases is less than that of prevalent (i.e., all existing) cases.

Entities:  

Mesh:

Year:  1998        PMID: 9894803     DOI: 10.1076/opep.5.4.173.4192

Source DB:  PubMed          Journal:  Ophthalmic Epidemiol        ISSN: 0928-6586            Impact factor:   1.648


  25 in total

1.  The effects of new topical treatments on management of glaucoma in Scotland: an examination of ophthalmological health care.

Authors:  D N Bateman; R Clark; A Azuara-Blanco; M Bain; J Forrest
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

2.  Appraising evaluations of screening/diagnostic tests: the importance of the study populations.

Authors:  R Harper; D Henson; B C Reeves
Journal:  Br J Ophthalmol       Date:  2000-10       Impact factor: 4.638

3.  Utility of predictive equations for estimating the prevalence and incidence of primary open angle glaucoma in the UK.

Authors:  D C Minassian; A Reidy; M Coffey; A Minassian
Journal:  Br J Ophthalmol       Date:  2000-10       Impact factor: 4.638

4.  Prevalence of primary open angle glaucoma in general ophthalmic practice in the United Kingdom.

Authors:  M Kroese; H Burton; S Vardy; T Rimmer; D McCarter
Journal:  Br J Ophthalmol       Date:  2002-09       Impact factor: 4.638

Review 5.  Primary open angle glaucoma. The need for a consensus case definition.

Authors:  M Kroese; H Burton
Journal:  J Epidemiol Community Health       Date:  2003-09       Impact factor: 3.710

6.  Ocular and systemic factors associated with glaucoma in chronic kidney disease patients.

Authors:  Jasmina Djordjevic-Jocic; Rade Cukuranovic; Branka Mitic; Predrag Jovanovic; Vidosava Djordjevic; Marija Mihajlovic; Aleksandar Veselinovic; Maja Zivkovic; Slavimir Veljkovic; Dragan Bogdanovic; Vladisav Stefanovic
Journal:  Int Urol Nephrol       Date:  2014-08-22       Impact factor: 2.370

7.  [Mastered with statistics: perfect eye drops and ideal screening test : Possibilities and limits of statistical methods for glaucoma].

Authors:  K E Kotliar; I M Lanzl
Journal:  Ophthalmologe       Date:  2016-10       Impact factor: 1.059

8.  Central corneal thickness in black Cameroonian ocular hypertensive and glaucomatous subjects.

Authors:  Christelle Domngang Noche; André Omgbwa Eballe; Assumpta Lucienne Bella
Journal:  Clin Ophthalmol       Date:  2010-11-24

9.  Rate and Pattern of Rim Area Loss in Healthy and Progressing Glaucoma Eyes.

Authors:  Na'ama Hammel; Akram Belghith; Christopher Bowd; Felipe A Medeiros; Lucie Sharpsten; Nadia Mendoza; Andrew J Tatham; Naira Khachatryan; Jeffrey M Liebmann; Christopher A Girkin; Robert N Weinreb; Linda M Zangwill
Journal:  Ophthalmology       Date:  2015-12-30       Impact factor: 12.079

10.  Intraocular pressure and visual field loss in primary angle closure and primary open angle glaucomas.

Authors:  G Gazzard; P J Foster; J G Devereux; F Oen; P Chew; P T Khaw; S Seah
Journal:  Br J Ophthalmol       Date:  2003-06       Impact factor: 4.638

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.